Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab + AG Adjuvant Therapy in EGFR+ Pancreatic Cancer
NCT06722911Phase 2Recruiting
- Sponsor
- Zhejiang Provincial People's Hospital
- Start
- Nov 2024
- Primary completion
- Sep 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Zhejiang Provincial People's Hospital. Primary endpoint: Disease-Free Survival at 24 months. Started Nov 2024; status: recruiting.
02
Drugs
nimotuzumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06722911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06722911.